Inherited retinal degenerations (IRDs) are a group of genetic disorders that lead to progressive vision loss as the light-sensing cells of the eye—the photoreceptors—die due to mutations in genes ...

Organ fragments grown in the laboratory will accelerate the testing of gene therapy methods for visual pathologies ...

A gene therapy that targets a form of retinitis pigmentosa showed a signal to improve retinal function for up to 3 years after treatment, according to a small clinical trial. The phase 2 SKYLINE trial ...

Adelaide University researchers have carried out the first in-human trial of a new type of treatment for a leading cause of ...

Ocugen is advancing gene-agnostic therapies targeting multiple retinal mutations with one-time treatments OCGN plans a 2026 BLA filing for OCU400, with phase III data expected in early 2027. Pipeline ...

Here we show that Cnga1-/-mice have a similar phenotype to human patients, characterized by an early loss of rod-mediated retinal function and progressive photoreceptor degeneration, which is nearly ...

An experimental MeiraGTx gene therapy that has clinical data showing reversal of blindness in children born with a rare, inherited eye disorder is heading to Eli Lilly. According to the terms of the ...

Opus Genetics, Inc., a clinical-stage biotechnology company focusing on gene therapies for inherited retinal diseases, announced upcoming presentations at various scientific conferences in May 2025.

Sports Chosun Jang Jong-ho] The development of a gene therapy for inherited retinal diseases is drawing closer.

Prior clinical successes with gene therapy for one of these diseases has raised hopes for patients and families affected by other such diseases, " says Editor-in-Chief Terence R. Flotte, MD, Celia and ...

No serious adverse events related to the therapy were reported. (iStock / Getty Images Plus) Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the ...

Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced its participation in two significant upcoming conferences: the ARVO 2025 Annual Meeting in Salt Lake ...